A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Taurine 4g is effective with antipsychotic medication in the treatment of First Episode Psychosis.Taurine may have an effect on cognition and symptoms. We are examining changes in symptoms and cognition over a 3 month period.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Melbourne Health
• Collaborators: Southern Health; Stanley Medical Research Institute
• Treatments: Antipsychotic Agents

Criteria

Inclusion Criteria:

• Male and females

• Between 18 and 25 years of age

• First Episode Psychosis

• Attending ORYGEN Youth Health, a geographical based catchment area service for young people aged between 15 and 25.

Exclusion Criteria:

• Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal lobe epilepsy, HIV encephalopathy)

• Mental retardation (unable and/or unlikely to give appropriate information of symptomatology or side-effects (IQ approximately lower than 80)

• History of clinically significant physical illness (e.g. terminal cancer, renal dialysis)

• History of brain surgery

• History of brain infarction

• Pregnant or lactating women or women of childbearing potential not using an acceptable method of contraception.